New antibody tested for Tough-to-Treat blood cancers
NCT ID NCT04681105
Summary
This early-stage trial tested a new antibody drug called flotetuzumab in 13 patients with advanced blood cancers that had returned or stopped responding to standard treatments. The main goal was to find the safest dose and understand the drug's side effects. Researchers also looked for early signs that the drug could help control these difficult cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.